Gi Insights

Guest: Andres J. Yarur, MD Obesity has recently surfaced as an important topic in patients with inflammatory bowel diseases, such as Crohn’s and ulcerative colitis, but historically, these patients have been underweight. This led to the phase III pivotal trials for the use of upadacitinib in patients with moderate to severe ulcerative colitis and Crohn’s disease to see how their baseline BMI would influence the efficacy of the drug. To hear the details and findings of this study, join Dr. Andres Yarur, Associate Professor of Medicine at Cedars Sinai Medical Center in Los Angeles, California. He also presented this study at Digestive Disease Week 2024.